Cargando…

Facilitation of Definitive Cancer Diagnosis With Quantitative Molecular Assays of BRAF V600E and TERT Promoter Variants in Patients With Thyroid Nodules

IMPORTANCE: Molecular testing of the presence of pathogenic genomic variants in a tumor without quantifying the variant allele fraction (VAF) does not differentiate the variation extent among tumors, often resulting in an inconclusive diagnosis because of interpatient variability. OBJECTIVE: To exam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Guodong, Chazen, Ronald S., Monteiro, Eric, Vescan, Allan, Freeman, Jeremy L., Witterick, Ian J., MacMillan, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383015/ https://www.ncbi.nlm.nih.gov/pubmed/37505499 http://dx.doi.org/10.1001/jamanetworkopen.2023.23500

Ejemplares similares

Development of a Molecular Assay for Detection and Quantification of the BRAF Variation in Residual Tissue From Thyroid Nodule Fine-Needle Aspiration Biopsy Specimens
por: Fu, Guodong, et al.
Publicado: (2021)

Preoperative detection of TERT promoter and BRAF(V600E) mutations in papillary thyroid carcinoma in high-risk thyroid nodules
por: Giorgenon, Tatiana Marina Vieira, et al.
Publicado: (2019)

Diagnostic Value of Galectin-3 in Distinguishing Invasive Encapsulated Carcinoma from Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features (NIFTP)†
por: Fu, Guodong, et al.
Publicado: (2021)

Programmed death-ligand 1 expression by digital image analysis advances thyroid cancer diagnosis among encapsulated follicular lesions
por: Hsieh, Anne M.-Y., et al.
Publicado: (2018)

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma
por: Gabler, Lisa, et al.
Publicado: (2019)

Mechanisms of TERT Reactivation and Its Interaction with BRAF(V600E)
por: Song, Young Shin, et al.
Publicado: (2020)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules
por: Rowe, Leslie R, et al.
Publicado: (2006)

Management of thyroid nodules with indeterminate fine-needle aspiration cytology: histogram analysis of greyscale sonograms and molecular assay of residual tissue from fine-needle aspiration biopsies
por: Fu, Guodong, et al.
Publicado: (2022)

Diagnostic utility of BRAF(V600E )mutation testing in thyroid nodules in elderly patients
por: Guerra, Anna, et al.
Publicado: (2013)

Utility of droplet digital polymerase chain reaction for TERT and BRAF mutational profiling of thyroid nodules
por: Rosvall, Brandon R., et al.
Publicado: (2021)

TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
por: Kim, Min Jhi, et al.
Publicado: (2022)

Proper Indication of BRAF(V600E) Mutation Testing in Fine-Needle Aspirates of Thyroid Nodules
por: Koh, Jieun, et al.
Publicado: (2013)

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China
por: Huang, Meiling, et al.
Publicado: (2019)

Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
por: Kim, Sue Youn, et al.
Publicado: (2020)

How do BRAF(V600E) and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?
por: Mukhtar, Noha, et al.
Publicado: (2023)

Detection of BRAF V600E in Fine-Needle Aspiration Samples of Thyroid Nodules by Droplet Digital PCR
por: Lu, Sang-Yu, et al.
Publicado: (2022)

Battle of the axes: simulation-based assessment of fine needle aspiration biopsies for thyroid nodules
por: Samargandy, Shireen, et al.
Publicado: (2022)

Evaluation of the Anyplex BRAF V600E Real-Time Detection Assay Using Dual-Priming Oligonucleotide Technology in Fine-Needle Aspirates of Thyroid Nodules
por: Choi, Rihwa, et al.
Publicado: (2015)

Value of TIRADS, BSRTC and FNA-BRAF(V600E) mutation analysis in differentiating high-risk thyroid nodules
por: Zhang, Yu-zhi, et al.
Publicado: (2015)

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
por: Liu, Rengyun, et al.
Publicado: (2018)

Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers
por: Wu, Yongxing, et al.
Publicado: (2021)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
por: Bae, Ja Seong, et al.
Publicado: (2016)

Co-existence of BRAF(V600E) and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis
por: Ren, Haoyu, et al.
Publicado: (2018)

Comparison Between Clinicopathological Characteristics, BRAF V600E and TERT Promoter Mutation of Familial Non-Medullary Thyroid Carcinomas, and Sporadic Case
por: Yang, Tian, et al.
Publicado: (2021)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay
por: Tatsuno, Michiko, et al.
Publicado: (2016)

Diagnostic value of BRAF(V600E)-mutation analysis in fine-needle aspiration of thyroid nodules: a meta-analysis
por: Su, Xingyun, et al.
Publicado: (2016)

Prospective Study of Bethesda Categories III and IV Thyroid Nodules: Outcomes and Predictive Value of BRAF(V600E) Mutation
por: Chirayath, Shiga Rappai, et al.
Publicado: (2019)

BRAF(V600E) vs. TIRADS in predicting papillary thyroid cancers in Bethesda system I, III, and V nodules
por: Wu, Ya, et al.
Publicado: (2019)

Comparison of the Clinical Validity of Droplet Digital PCR to ARMS‐PCR for BRAF V600E Mutation Detection in Thyroid Nodules
por: Li, Xiubo, et al.
Publicado: (2020)

BRAF(V600E) mutation test on fine‐needle aspiration specimens of thyroid nodules: Clinical correlations for 4600 patients
por: Chen, Huang, et al.
Publicado: (2021)

Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
por: Kang, So Young, et al.
Publicado: (2013)

Cribriform adenocarcinoma of the minor salivary glands: a case report
por: Chen, Tanya, et al.
Publicado: (2023)

Diagnostic Efficacy of Ultrasound, Cytology, and BRAF(V600E) Mutation Analysis and Their Combined Use in Thyroid Nodule Screening for Papillary Thyroid Microcarcinoma
por: Du, Jing, et al.
Publicado: (2022)

Is Follow-up BRAF(V600E) Mutation Analysis Helpful in the Differential Diagnosis of Thyroid Nodules with Negative Results on Initial Analysis?
por: Yoon, Jung Hyun, et al.
Publicado: (2013)

Increased diagnostic sensitivity of palpation‐guided thyroid nodule fine‐needle aspiration cytology by BRAF V600E‐mutation analysis
por: Gimm, Oliver, et al.
Publicado: (2021)

BRAF(V600E) genetic testing should be recommended for Bethesda III or V thyroid nodules based on fine-needle aspiration
por: Lu, Yiran, et al.
Publicado: (2023)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_29uq4a8460v4fmjoe57tsl73ad